Search research articles
Contact Us
Filters
Showing results (31-40 of 40) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 40 results.
JCO Precision Oncology
|
February 6, 2025
Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H
Mohamed A Gouda, Zihan Wei, Jordi Rodon, et al.
JCO Precision Oncology
|
October 9, 2025
Phase II Study of Vismodegib in Patients With <i>SMO-</i> or <i>PTCH1</i>-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T
Anne S Tsao, Zihe Song, Alan L Ho, et al.
Nature Medicine
|
June 15, 2023
The NCI-MATCH trial: lessons for precision oncology
Peter J O'Dwyer, Robert J Gray, Keith T Flaherty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 27, 2021
Differential Outcomes in Codon 12/13 and Codon 61 <i>NRAS</i>-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with <i>NRAS</i>-Mutated Tumors
James M Cleary, Victoria Wang, Rebecca S Heist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 20, 2026
Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2
Niamh Coleman, Zihan Wei, A John Iafrate, et al.
JAMA Oncology
|
July 17, 2025
Risk Factors for COVID-19-Related Hospitalization and Death in Patients With Cancer: The National Cancer Institute COVID-19 in Cancer Patients Study (NCCAPS)
Brian I Rini, Ana F Best, Mel D Bowman, et al.
JCO Precision Oncology
|
February 9, 2022
Phase II Study of Taselisib in <i>PIK3CA</i>-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I
Ian E Krop, Opeyemi A Jegede, Juneko E Grilley-Olson, et al.
JCO Precision Oncology
|
June 17, 2026
Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I
Shivaani Kummar, Zihe Song, Kim A Reiss, et al.
Nature Medicine
|
January 6, 2025
Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial
Andrea M Gross, Geraldine O'Sullivan Coyne, Eva Dombi, et al.
Journal of the National Cancer Institute
|
January 11, 2020
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design
Keith T Flaherty, Robert Gray, Alice Chen, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 40) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 40 results.
JCO Precision Oncology
|
February 6, 2025
Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H
Mohamed A Gouda, Zihan Wei, Jordi Rodon, et al.
JCO Precision Oncology
|
October 9, 2025
Phase II Study of Vismodegib in Patients With <i>SMO-</i> or <i>PTCH1</i>-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T
Anne S Tsao, Zihe Song, Alan L Ho, et al.
Nature Medicine
|
June 15, 2023
The NCI-MATCH trial: lessons for precision oncology
Peter J O'Dwyer, Robert J Gray, Keith T Flaherty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 27, 2021
Differential Outcomes in Codon 12/13 and Codon 61 <i>NRAS</i>-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with <i>NRAS</i>-Mutated Tumors
James M Cleary, Victoria Wang, Rebecca S Heist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 20, 2026
Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2
Niamh Coleman, Zihan Wei, A John Iafrate, et al.
JAMA Oncology
|
July 17, 2025
Risk Factors for COVID-19-Related Hospitalization and Death in Patients With Cancer: The National Cancer Institute COVID-19 in Cancer Patients Study (NCCAPS)
Brian I Rini, Ana F Best, Mel D Bowman, et al.
JCO Precision Oncology
|
February 9, 2022
Phase II Study of Taselisib in <i>PIK3CA</i>-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I
Ian E Krop, Opeyemi A Jegede, Juneko E Grilley-Olson, et al.
JCO Precision Oncology
|
June 17, 2026
Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I
Shivaani Kummar, Zihe Song, Kim A Reiss, et al.
Nature Medicine
|
January 6, 2025
Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial
Andrea M Gross, Geraldine O'Sullivan Coyne, Eva Dombi, et al.
Journal of the National Cancer Institute
|
January 11, 2020
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design
Keith T Flaherty, Robert Gray, Alice Chen, et al.
Page
of 4